Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This decline occurred after Anavex withdrew its application for marketing authorization of blarcamesine in the EU, a decision that followed negative feedback from the European Medicines Agency. The firm is encouraging investors who purchased Anavex securities to participate in the investigation, noting that it represents investors on a contingency fee basis.
Bronstein, Gewirtz & Grossman, LLC Is Investigating Anavex Life Sciences Corp. (AVXL) And Encourages Investors to Connect
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This comes after Anavex withdrew its application for blarcamesine's marketing authorization in the EU, a drug for early Alzheimer's disease, due to negative feedback from the European Medicines Agency. The firm is encouraging investors who purchased Anavex securities to contact them for more information regarding potential claims.
Bronstein, Gewirtz & Grossman, LLC Encourages Anavex Life Sciences Corp. (AVXL) Stockholders to Inquire about Securities Investigation
Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Anavex Life Sciences Corp. (AVXL) securities following a significant stock price drop. The drop occurred after Anavex withdrew its application for marketing authorization of blarcamesine in the EU, a decision made after feedback from the European Medicines Agency indicated a positive opinion was unlikely. Anavex investors are encouraged to contact the firm for more information and to assist with the investigation.
Anavex Life Sciences (Nasdaq:AVXL) - Stock Analysis
This report provides a comprehensive stock analysis of Anavex Life Sciences (Nasdaq:AVXL), a biopharmaceutical company focused on neurological disorder therapies. It highlights the company's current stock performance, market capitalization, analyst consensus target price of US$22 (86.4% undervalued), and future growth prospects with earnings forecast to grow 60.57% per year. The analysis also covers its pipeline, financial health, risk factors, and recent news regarding its drug development programs, particularly Blarcamesine, for conditions like Alzheimer's and Parkinson's disease.
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Anavex Life Sciences Corp. (AVXL) and Encourages Investors to Learn More About the Investigation
Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Anavex Life Sciences Corp. (AVXL) following a significant drop in its stock price. This decline occurred after Anavex withdrew its application for marketing authorization of blarcamesine for early Alzheimer's disease in the EU, a decision prompted by feedback from the European Medicines Agency. The firm is encouraging investors who purchased Anavex securities to join their investigation into potential claims.
AVXL Earning Date, Earning Analysis and Earning Prediction
The article provides an earnings analysis and prediction for AVXL (Anavex Life Sciences Corp), detailing past quarterly results and future forecasts. It highlights unchanged revenue and EPS estimates for FY2025 and Q2 2025, and discusses the correlation between earnings revisions and stock price movements. The piece also includes a summary of historical stock reactions around earnings reports and addresses frequently asked questions regarding AVXL's financial performance and outlook.
Anavex Life Sciences Provides Comprehensive Regulatory Update
Anavex Life Sciences has provided a comprehensive regulatory update, continuing dialogue with the European Medicines Agency (EMA) to advance the development program for oral blarcamesine in early Alzheimer’s disease. The company has also submitted additional data to the U.S. FDA to discuss potential pathways for a New Drug Application (NDA) for early Alzheimer's. Furthermore, Anavex is engaging with EU regulators for blarcamesine in Parkinson’s disease and rare diseases like Rett syndrome, showcasing the breadth of its clinical development.
After withdrawing its EU filing, Anavex keeps Alzheimer’s drug in talks
Anavex Life Sciences provided a regulatory update, withdrawing its EU marketing application for blarcamesine in early Alzheimer's to gather more data and address EMA questions. Concurrently, the company submitted additional data to the FDA to align on a New Drug Application pathway for early Alzheimer's and is engaging EU regulators for blarcamesine in Parkinson’s disease and Rett syndrome. This update emphasizes Anavex's continued commitment to developing innovative oral therapies despite regulatory setbacks.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Anavex Life Sciences Corp. - AVXL
Pomerantz LLP is investigating potential claims on behalf of investors of Anavex Life Sciences Corp. (NASDAQ: AVXL) following the withdrawal of its blarcamesine marketing authorization application in the EU. This decision came after feedback from the European Medicines Agency's Committee for Medicinal Products Human Use (CHMP), which indicated it would not issue a positive opinion. The news led to a significant drop in Anavex's stock price, prompting the law firm's investigation into possible securities fraud.
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences Corp. (NASDAQ: AVXL) shares plummeted after the company withdrew its application for marketing authorization of blarcamesine in the EU for early Alzheimer’s disease. This decision followed negative feedback from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Health (CHMP). The company plans to gather additional data and analyses to address the CHMP's concerns, while also discussing potential pathways for a New Drug Application with the U.S. FDA.
AVXL Plummets 31% to 52-Week Lows: A Technical Meltdown Ignites the Biotech Watchlist
Anavex Life Sciences (AVXL) experienced a catastrophic 31.5% intraday collapse, hitting a new 52-week low despite a resilient broader biotech sector. The plunge is attributed to a technical breakdown, aggressive profit-taking, and a loss of confidence among institutional holders, rather than specific company news. With key support levels breached and oversold conditions, the immediate outlook is precarious, urging investors to watch the $2.85 mark for potential reversal signals.
Anavex Life Sciences withdraws EU marketing application for blarcamesine after CHMP feedback
Anavex Life Sciences has withdrawn its EU marketing authorization application for blarcamesine, intended as an add-on therapy for early Alzheimer’s disease. The decision follows feedback from the CHMP, indicating it would not be in a position to issue a positive opinion at this time. Anavex plans to gather additional data and further analyses while remaining committed to ongoing clinical development.
Anavex (NASDAQ: AVXL) withdraws EU Alzheimer’s drug application for blarcamesine
Anavex Life Sciences Corp. has withdrawn its application for EU marketing authorization of blarcamesine as an add-on therapy for early Alzheimer’s disease. This decision follows feedback from the European Medicines Agency’s CHMP indicating it would not issue a positive opinion at this time. Anavex remains committed to blarcamesine's development and plans to gather additional data to address the CHMP's concerns.
Anavex Life Sciences Corp Faces Competitive Pressure Amid Financial Year Results
Anavex Life Sciences Corp. (NASDAQ: AVXL) has seen its stock drop by over 30% following unimpressive clinical trial results and an operating loss of $6.78M due to high R&D expenses. Despite financial volatility and investor wariness, the company maintains a strong cash position of $131.75M and a zero-debt-to-equity ratio, indicating financial resilience. The market's reaction hinges on whether Anavex's ongoing research investments will translate into significant breakthroughs and future financial success.
Anavex Life Sciences Stock Crushed As European Alzheimer's Drug Filing Pulled After EMA Pushback
Anavex Life Sciences' stock fell significantly after the company withdrew its application for marketing authorization of blarcamesine, an Alzheimer's drug, in the EU. This decision came after the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) indicated it would not issue a positive opinion. Anavex plans to gather additional data and conduct further analyses to address the CHMP's concerns, while also exploring pathways for a New Drug Application with the U.S. FDA.
Anavex Life Sciences Corp. (AVXL) recently disclosed the latest updates on the regulatory review of its investigational drug Blarcamesine for early Alzheimer’s disease in the European Union.
Anavex Life Sciences Corp. (AVXL) has provided updates on the regulatory review process for its drug Blarcamesine, intended for early Alzheimer's disease, within the European Union. This disclosure aims to inform investors about the progress of this potential treatment. The article emphasizes that its content is solely the author's opinion and not financial advice from the platform.
Anavex Life Sciences stock tumbles after EU filing withdrawal
Anavex Life Sciences (NASDAQ:AVXL) shares fell 12% after the company withdrew its marketing authorization application for blarcamesine in the European Union, intended as a treatment for early Alzheimer’s disease. The withdrawal occurred because the European Medicines Agency's Committee for Medicinal Products for Human Use indicated it would not issue a positive opinion at this time. Anavex plans to gather additional data and conduct further analyses to address the issues raised by the committee.
EU review halts Anavex’s Alzheimer’s drug bid, more data next
Anavex Life Sciences (Nasdaq: AVXL) withdrew its EU marketing authorization application for blarcamesine for early Alzheimer's disease after the EMA's CHMP indicated it would not issue a positive opinion at this time. The company plans to gather additional data, conduct further analyses, and continue clinical development to address the CHMP's feedback. This news led to a significant negative market reaction, with AVXL shares declining by 32.46%.
Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease
Anavex Life Sciences announced the withdrawal of its marketing authorization application for blarcamesine in the EU for early Alzheimer's disease, following feedback from the European Medicines Agency's (EMA) CHMP indicating a positive opinion was unlikely at this time. The company stated it will consider the feedback to gather additional data and analyses to address the points raised, affirming its commitment to developing innovative oral therapies for Alzheimer's patients. Anavex highlighted its intent to engage further with regulatory authorities despite the current setback, which came after initial encouragement from the EMA's SME office.
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Anavex Life Sciences presented new data from its AD-004 Phase IIb/III trial at the AD/PD 2026 Conference, highlighting a consistent correlation between oral blarcamesine treatment and the preservation of brain volume in early Alzheimer’s disease. The data indicate that blarcamesine's clinical effects are biologically consistent with neuroprotection measured by MRI, particularly benefiting a genetically defined patient population. Long-term clinical data also suggest significant time saved in cognitive decline compared to a control group, reinforcing blarcamesine's potential as a disease-modifying treatment.
Study ties oral Alzheimer’s drug to slower brain shrinkage
Anavex Life Sciences presented new data from its AD-004 Phase IIb/III trial for blarcamesine in early Alzheimer's disease, showing a consistent correlation between the treatment and preservation of brain volume. The findings indicate patients treated with oral blarcamesine experienced 77.4 weeks of time saved versus a control group and highlight a strong MRI-clinical endpoint coherence, particularly in a genetically defined subgroup. While results are investigational, the company emphasizes the drug's oral convenience and potential for precision medicine in Alzheimer's treatment.
Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease
Anavex Life Sciences presented new data from its Phase IIb/III AD-004 trial at the AD/PD™ 2026 Conference, highlighting a consistent correlation between oral blarcamesine treatment and the preservation of brain volume in early Alzheimer's disease. The data also indicated that blarcamesine may offer substantial clinical and structural benefits, particularly for patients with wild-type SIGMAR1 and COL24A1 genes (ABCLEAR32 population). These findings reinforce Anavex's precision medicine strategy and suggest blarcamesine's potential as a disease-modifying treatment.
Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights
Anavex Life Sciences announced new peer-reviewed study findings supporting the hypothesis that autophagy impairment is an early and addressable factor in Alzheimer's disease, preceding amyloid beta and tau pathology. The company's lead drug, blarcamesine, targets this mechanism by restoring neural autophagy. Despite a recent negative opinion from the European medicines Agency, Anavex is exploring NDA pathways with the FDA and has a cash runway of over three years.
Form 8K Anavex Life Sciences Corp For: 9 February
This article announces the filing of a Form 8K by Anavex Life Sciences Corp for February 9th. It also includes standard disclaimers about the risks associated with trading financial instruments and cryptocurrencies, emphasizing that data on the platform may not be real-time or accurate.
Anavex Life Sciences (NasdaqGS:AVXL) Stock Forecast & Analyst Predictions
Anavex Life Sciences (AVXL) is a clinical-stage biopharmaceutical company focused on therapies for neurological disorders. Analysts predict significant future growth, with earnings forecast to increase by 60.6% and revenue by 44% per annum. The company is expected to become profitable within the next three years, outpacing the average market growth and savings rate.
Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference
Anavex Life Sciences announced new data at the AD/PD 2026 Conference showing that blarcamesine significantly improved motor function and promoted dopaminergic nerve fiber regrowth in an advanced Parkinson's disease model. This model addresses both alpha-synuclein pathology and noradrenergic degeneration, mimicking key aspects of the disease. The findings are highly encouraging, suggesting blarcamesine's potential as a disease-modifying therapeutic for Parkinson’s disease.
Parkinson’s therapy hope: blarcamesine regrows nerve fibers in lab model
Anavex Life Sciences announced new preclinical data for blarcamesine, showing it completely restored impaired motor function and promoted dopaminergic nerve fiber regrowth in a new advanced Parkinson's disease model. These results, presented at the AD/PD 2026 Conference, support the company's decision to advance blarcamesine into clinical development for early Parkinson's disease. The dual-hit model mimics key aspects of Parkinson's by combining alpha-synuclein accumulation and noradrenergic degeneration.
Anavex Life Sciences to Present at the Citizens Life Sciences Conference
Anavex Life Sciences Corp. announced that its President & CEO, Christopher U Missling, PhD, will present at the Citizens Life Sciences Conference on March 10, 2026, at 11:55 AM (ET). The company is a clinical-stage biopharmaceutical firm focused on developing innovative treatments for various neurological disorders including Alzheimer's disease and Parkinson's disease. Anavex highlights its lead drug candidate, ANAVEX®2-73 (blarcamesine), which has undergone several clinical trials for Alzheimer's, Parkinson's, and Rett syndrome, and also mentions ANAVEX®3-71 for Alzheimer's disease.
Alzheimer's-focused Anavex CEO to speak at Citizens Life Sciences Conference
Anavex Life Sciences (Nasdaq: AVXL) CEO, Christopher U Missling, PhD, is scheduled to present at the Citizens Life Sciences Conference on Tuesday, March 10, 2026, at 11:55 AM ET. The presentation will cover the company's clinical-stage CNS programs, including therapies for Alzheimer's, Parkinson's, schizophrenia, Rett syndrome, and other neurodegenerative and rare diseases. This event is part of Anavex's ongoing investor relations efforts to increase awareness of its pipeline.
Anavex Life Sciences (AVXL) names healthcare leader Axel Paeger to board
Anavex Life Sciences (AVXL) has appointed Dr. Axel Paeger to its Board of Directors, effective February 23, 2026, to fill an existing vacancy. Dr. Paeger, a healthcare leader with over 30 years of experience, including as CEO of the AMEOS Group, will receive compensation consistent with other non-employee directors and has been determined to be an independent director. This appointment aims to leverage his extensive experience to advance Anavex's mission in developing treatments for neurological disorders.
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
Anavex Life Sciences Corp. announced that its President & Chief Executive Officer, Christopher U Missling, PhD, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 11:50 AM ET. The company, focused on developing treatments for various neurological disorders, will provide a live audio webcast and an archived edition of the session via its investors' section. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has completed multiple clinical trials for Alzheimer’s, Parkinson’s, and Rett syndromes.
Anavex Adds Veteran Healthcare Leader to Board of Directors
Anavex Life Sciences announced the appointment of Dr. Axel Paeger, CEO and founder of Europe’s AMEOS Group, as an independent director to its board. Dr. Paeger brings over 30 years of experience in inpatient medical and psychiatric care, which is expected to support Anavex's focus on its CNS pipeline and precision medicine approach in neurology. Anavex (AVXL) currently holds a Neutral rating from Spark, TipRanks’ AI Analyst, due to weak financial fundamentals, soft technicals, and regulatory uncertainty in the EU, despite improved liquidity and expense reductions.
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
Anavex Life Sciences Corp. announced that its President & CEO, Christopher U Missling, PhD, will present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026, at 11:50 AM ET. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. The presentation will discuss their innovative therapies, including ANAVEX®2-73 and ANAVEX®3-71, for conditions like Alzheimer's and Parkinson's disease.
Alzheimer’s treatment developer Anavex to speak at TD Cowen health conference
Anavex Life Sciences (Nasdaq: AVXL) announced that its President & CEO, Christopher U Missling, PhD, will present at the 46th TD Cowen Annual Health Care Conference on March 2, 2026, at 11:50 AM ET. The presentation will cover the company's clinical-stage programs, particularly for Alzheimer's and Rett syndrome, and will be accessible via a live audio webcast on Anavex's investor relations website, with an archived version available later. This event is primarily for investor visibility, building on recent positive company news regarding leadership, financial updates, and pipeline progress.
EBITDA per share of Anavex Life Sciences Corp. – LSE:0HFR
This article provides financial information for Anavex Life Sciences Corp. (LSE:0HFR), specifically focusing on its EBITDA per share. It mentions the period, value, change, and percentage change for this metric, suggesting it's an excerpt from a financial data platform.
Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference
Anavex Life Sciences Corp. announced that its President & CEO, Christopher U Missling, PhD, will present at the 46th TD Cowen Annual Health Care Conference on March 2, 2026. The company is a clinical-stage biopharmaceutical firm focused on developing treatments for neurodegenerative, neurodevelopmental, and neuropsychiatric disorders. Their lead drug candidate, ANAVEX®2-73 (blarcamesine), has shown promise in clinical trials for Alzheimer's disease, Parkinson's disease dementia, and Rett syndrome.
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
Anavex Life Sciences Corp. has appointed Dr. Axel Paeger, MD, MBA, MBI, to its Board of Directors. Dr. Paeger brings over 30 years of experience in healthcare, currently serving as CEO of the AMEOS Group, a leading European healthcare provider. His expertise is expected to be instrumental in guiding Anavex's strategy for developing new medicines for neurological disorders.
Anavex Life Sciences Corp. CEO to Present at TD Cowen 46th Annual Health Care Conference on March 2, 2026
Anavex Life Sciences Corp. will have its CEO, Dr. Christopher U. Missling, present at the TD Cowen 46th Annual Health Care Conference on March 2, 2026. The company will discuss its innovative CNS therapies, including lead candidates ANAVEX®2-73 and ANAVEX®3-71, for neurodegenerative and psychiatric disorders like Alzheimer's and Parkinson's diseases, and Rett syndrome. A live audio webcast of the presentation will be available on the company's website.
Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors
Anavex Life Sciences Corp. (Nasdaq: AVXL) has appointed Dr. Axel Paeger, MD, MBA, MBI, a seasoned healthcare leader with over 30 years of experience, to its Board of Directors. Dr. Paeger, CEO of the AMEOS Group, is expected to provide invaluable guidance as Anavex advances its mission of developing new medicines for neurological disorders. This appointment aims to strengthen Anavex's strategic evolution and progress its late-stage candidates for CNS disorders.
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
Anavex Life Sciences reported its financial results for the fourth quarter and fiscal year ended September 30, 2024, highlighting recent advancements in its investigational treatments, particularly for Alzheimer's disease. The company announced the European Medicines Agency (EMA) accepted for review the Marketing Authorization Application (MAA) for blarcamesine (ANAVEX®2-73) and presented encouraging preliminary data for ANAVEX®3-71 for schizophrenia. Anavex finished the fiscal year with $132.2 million in cash and cash equivalents, projecting approximately four years of runway at the current cash utilization rate.
Anavex Life Sciences (NASDAQ:AVXL) Upgraded at Wall Street Zen
Anavex Life Sciences (NASDAQ:AVXL) was upgraded by Wall Street Zen from "sell" to "hold," resulting in a consensus "Hold" rating and a $22.00 target price. Despite beating quarterly EPS estimates, the company faces a negative FY2026 EPS outlook, with its stock trading below key moving averages. Institutional ownership has increased, with State Street Corp significantly boosting its stake, now holding approximately 31.55% of the company's shares.
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q1 2026 Earnings Call Transcript
Anavex Life Sciences Corp. discussed its Q1 2026 financial results and advancements in its clinical pipeline, particularly for oral blarcamesine in early Alzheimer's disease. The company addressed the EMA's negative opinion on blarcamesine's marketing authorization application, stating it is undergoing reexamination, and detailed plans for an upcoming FDA submission. Anavex also highlighted its participation in the European Access AD initiative, which will include a dedicated clinical trial for blarcamesine.
ANAVEX LIFE SCIENCES CORP. SEC 10-Q Report
Anavex Life Sciences Corp. released its Form 10-Q report for the third quarter, reporting significantly improved financial performance with reduced operating and net losses. The biopharmaceutical company highlighted operational advancements, including ongoing clinical trials for central nervous system diseases like Alzheimer's and Parkinson's, regulatory submissions, and a precision medicine approach. Anavex plans to continue advancing its clinical programs and seek strategic partnerships, leveraging its Orphan Drug and Fast Track designations for ANAVEX®2-73.
Anavex Life Sciences: Fiscal Q1 Earnings Snapshot
Anavex Life Sciences Corp. (AVXL) reported a fiscal first-quarter loss of $5.7 million, or 6 cents per share. The company's shares closed at $4.10, a significant decrease from $8.51 a year ago. This financial update was generated by Automated Insights using Zacks Investment Research data.
Anavex (Nasdaq: AVXL) narrows Q1 loss and boosts cash reserves
Anavex Life Sciences Corp. reported a significantly narrower net loss of $5.7 million in fiscal Q1 2026, down from $12.1 million in the prior year, primarily due to reduced operating expenses. The company also strengthened its cash reserves, ending the quarter with $131.7 million, and continues to focus on advancing its lead candidate, blarcamesine, for Alzheimer's and other CNS disorders. Anavex anticipates a cash runway of over three years at its current utilization rate.
Anavex Life Sciences: Overview of Fiscal First Quarter Earnings
Anavex Life Sciences has reported a net loss of $5.7 million for its fiscal first quarter, translating to a loss of $0.06 per share. The company's shares closed at $4.10, marking a substantial drop from $8.51 recorded in the same period last year. This financial update details the company's performance for the quarter.
Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update
Anavex Life Sciences reported its financial results for the first quarter of fiscal 2026, highlighting significant progress in its clinical pipeline, particularly with blarcamesine for early Alzheimer's disease. The company outlined key development milestones, including regulatory updates for blarcamesine in various CNS disorders and upcoming scientific presentations. Financially, Anavex ended the quarter with $131.7 million in cash, projecting a cash runway of over three years.
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences announced that it will release its fiscal 2026 first quarter financial results on Monday, February 9, 2026. The company is focused on developing innovative oral medicines to improve the lives of patients with brain health conditions, including Alzheimer's, Parkinson's, and Rett Syndrome. This announcement provides investors and the public with the scheduled date for their upcoming financial report.
Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026
Anavex Life Sciences announced that it will release its fiscal first-quarter 2026 financial results on Monday, February 9, 2026. The company will also host a conference call and webcast on the same day at 8:30 am ET to discuss the financial results and recent corporate developments, followed by a question-and-answer session. A replay of the conference call will be available on Anavex’s website for up to 30 days.
Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology
Anavex Life Sciences has appointed Wolfgang Liedtke, MD, PhD, as Senior Vice President, Global Head of Neurology. Dr. Liedtke brings over 25 years of experience in neurological medicine development, including significant roles at Regeneron and Duke University. His appointment is expected to bolster Anavex's mission to develop innovative treatments for neurodegenerative and neuropsychiatric disorders, focusing on patient-oriented precision medicine.
